Vivo Opportunity, LLC's Form 4 filing
InMed Pharmaceuticals Inc.INM · filed Jul 2, 2026
- Accession no.
- 0001213900-26-075144
- Filed
- Jul 2, 2026, 7:02 PM ET
- Trade date
- Jun 30-Jul 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market purchases total $10.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Opportunity Cayman Fund, L.P.CIK 0001875722 | 10% Owner |
| Vivo Opportunity Cayman, LLCCIK 0001930113 | 10% Owner |
| Vivo Opportunity Fund Holdings, L.P.CIK 0001930214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Common Shares | PPurchaseAcquired | +545 | $1.54F3 | +$839.3 | 718,989 | Indirect | |
| Jun 30, 2026 | Common Shares | PPurchaseAcquired | +55 | $1.54F3 | +$84.7 | 72,590 | Indirect | |
| Jul 1, 2026 | Common Shares | PPurchaseAcquired | +3,946 | $1.55F4 | +$6,116.3 | 722,935 | Indirect | |
| Jul 1, 2026 | Common Shares | PPurchaseAcquired | +398 | $1.55F4 | +$616.9 | 72,988 | Indirect | |
| Jul 2, 2026 | Common Shares | PPurchaseAcquired | +1,460 | $1.55F5 | +$2,263 | 724,395 | Indirect | |
| Jul 2, 2026 | Common Shares | PPurchaseAcquired | +147 | $1.55F5 | +$227.85 | 73,135 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
Referenced by the price of 2 transactions in Table I.